Context: Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAV , the most rigorous IVUS measure of disease progression and regression. Objective: To assess whether very intensive statin therapy could regress coronary atherosclerosis as determined by IVUS imaging. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment. Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion.

Author:Akinodal Nashicage
Language:English (Spanish)
Published (Last):18 August 2019
PDF File Size:18.16 Mb
ePub File Size:19.45 Mb
Price:Free* [*Free Regsitration Required]

When we see less plaque after a treatment period, all the limitations aside, we believe it will be confirmed with a morbidity and mortality benefit. All patients were treated with rosuvastatin Crestor, AstraZeneca at 40 mg daily. Researchers assessed coronary atheroma burden by IVUS at 24 months. Of the patients treated with rosuvastatin, withdrew or did not have a viable IVUS reading, which left patients available for evaluation.

Nissen said the patients who withdrew were nearly identical to the ones that remained in terms of age mean age was LDL at baseline was Treatment with rosuvastatin was associated with a reduction of When researchers measured percent atheroma volume for the entire cohort, they found that For the most diseased 10 mm subsegment, regression occurred in The treatment regimen was well tolerated.

Liver enzymes were at levels similar to that seen in other statin trials and no cases of rhabdomyolysis were reported. Healio News Cardiology Imaging. Issue: April Read Next. April 01, Receive an email when new articles are posted on. Please provide your email address to receive an email when new articles are posted on. You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice slackinc. Back to Healio. Related Content.


ASTEROID: IVUS shows regression with rosuvastatin

Rosuvastatin therapy lowered low-density lipoprotein cholesterol to This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events. This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable.

ASTM E 1381-95 PDF


The top left panel illustrates the appearance of a single cross-section at baseline intravascular ultrasound examination, while the top right panel shows the same cross-section after 24 months of treatment. The bottom 2 panels illustrate the same cross-sections, but with measurements superimposed. Atheroma area was reduced from EEM indicates external elastic membrane.

Related Articles